Chemistry:Propylallyltryptamine

From HandWiki

Propylallyltryptamine (PALT), also known as N-propyl-N-allyltryptamine or by its developmental code name ASR-3004, is a serotonin receptor modulator of the tryptamine family.[1] It is an asymmetrical analogue of dipropyltryptamine (DPT) and diallyltryptamine (DALT).[1] The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT6 receptors, but not of the serotonin 5-HT1A receptor.[1] It is also a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI).[1] The chemical synthesis of PALT has been described.[1] A notable analogue of PALT is iPALT (ASR-3003).[1] PALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.[1]

See also

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Daley PF, Cozzi NV, Callaway WB, "Asymmetric allyl tryptamines", US patent 20240277665A1, issued 4 March 2024, assigned to Alexander Shulgin Research Institute Inc.